All News

Dapagliflozin, sold by AstraZeneca as Farxiga, cut the risk of cardiovascular (CV) death and worsening of heart failure (HF) by 26% among patients with reduced ejection fraction alongside standard of care, according to results of a landmark phase 3 study presented Sunday at the European Society of Cardiology 2019 Congress. Results confirmed that the sodium glucose co-transporter 2 (SGLT2) inhibitor, already approved to treat type 2 diabetes (T2D), is just as effective in preventing CV death and HF events in patients who do not have T2D.

This week, the top managed care stories included a huge ruling against one opioid maker and a settlement offer from another; an expert panel calling for broader screening for hepatitis C; a review showing there are more fatal events linked to a multiple sclerosis drug than previously known.

A new government analysis revealed that despite a previous warning, CMS failed to take steps to ensure that Medicare Part D does not also pay for drugs that should be covered under the Part A hospice benefit; with studies of antidepressants’ safety and efficacy only following patients for a few years and with more people taking antidepressants for longer periods of time, health professionals are concerned that some people taking the drugs for extended periods shouldn’t be and are thus subjecting themselves to side effects and potential health risks; Medicaid advocates in Nebraska have filed a lawsuit to try and force the state to implement Medicaid expansion no later than November 17, 2019.

Purdue Pharma is offering up to $12 billion to settle lawsuits over its role in the opioid epidemic; the US Preventive Services Task Force is aiming to expand its hepatitis C virus (HCV) screening recommendations to include all adults aged 18 to 79 years; the majority of Democratic voters would be more likely to support a candidate that backs a single-payer health system like Medicare for All.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text